Han Xudong, Wang Donghua, Zhao Ping, Liu Chonghui, Hao Yue, Chang Lulu, Zhao Jiarui, Zhao Wei, Mu Lili, Wang Jinghua, Li Hulun, Kong Qingfei, Han Junwei
Department of Neurobiology, Harbin Medical University, Heilongjiang Provincial Key Laboratory of Neurobiology, Harbin, China.
Department of General Surgery, General Hospital of Heilongjiang Province Land Reclamation Bureau, Harbin, China.
Front Oncol. 2020 Sep 11;10:1549. doi: 10.3389/fonc.2020.01549. eCollection 2020.
Glioblastoma, also known as glioblastoma multiforme (GBM), is the most malignant form of glioma and represents 81% of malignant brain and central nervous system (CNS) tumors. Like most cancers, GBM causes metabolic recombination to promote cell survival, proliferation, and invasion of cancer cells. In this study, we propose a method for constructing the metabolic subpathway activity score matrix to accurately identify abnormal targets of GBM metabolism. By integrating gene expression data from different sequencing methods, our method identified 25 metabolic subpathways that were significantly abnormal in the GBM patient population, and most of these subpathways have been reported to have an effect on GBM. Through the analysis of 25 GBM-related metabolic subpathways, we found that (S)-2,3-Epoxysqualene, which was at the central region of the sterol biosynthesis subpathway, may have a greater impact on the entire pathway, suggesting a potential high association with GBM. Analysis of CCK8 cell activity indicated that (S)-2,3-Epoxysqualene can indeed inhibit the activity of U87-MG cells. By flow cytometry, we demonstrated that (S)-2,3-Epoxysqualene not only arrested the U87-MG cell cycle in the G0/G1 phase but also induced cell apoptosis. These results confirm the reliability of our proposed metabolic subpathway identification method and suggest that (S)-2,3-Epoxysqualene has potential therapeutic value for GBM. In order to make the method more broadly applicable, we have developed an R system package crmSubpathway to perform disease-related metabolic subpathway identification and it is freely available on the GitHub (https://github.com/hanjunwei-lab/crmSubpathway).
胶质母细胞瘤,也称为多形性胶质母细胞瘤(GBM),是最恶性的胶质瘤形式,占恶性脑和中枢神经系统(CNS)肿瘤的81%。与大多数癌症一样,GBM会引起代谢重组,以促进癌细胞的存活、增殖和侵袭。在本研究中,我们提出了一种构建代谢子通路活性评分矩阵的方法,以准确识别GBM代谢的异常靶点。通过整合来自不同测序方法的基因表达数据,我们的方法确定了25条在GBM患者群体中显著异常的代谢子通路,其中大多数子通路已被报道对GBM有影响。通过对25条与GBM相关的代谢子通路的分析,我们发现位于甾醇生物合成子通路中心区域的(S)-2,3-环氧角鲨烯可能对整个通路有更大影响,这表明它与GBM可能有高度相关性。CCK8细胞活性分析表明,(S)-2,3-环氧角鲨烯确实可以抑制U87-MG细胞的活性。通过流式细胞术,我们证明(S)-2,3-环氧角鲨烯不仅使U87-MG细胞周期停滞在G0/G1期,还诱导细胞凋亡。这些结果证实了我们提出的代谢子通路识别方法的可靠性,并表明(S)-2,3-环氧角鲨烯对GBM具有潜在的治疗价值。为了使该方法更广泛适用,我们开发了一个R系统包crmSubpathway来进行疾病相关的代谢子通路识别,它可在GitHub(https://github.com/hanjunwei-lab/crmSubpathway)上免费获取。